Maralixibat Takes Out the Itch of Rare Liver Disease
(MedPage Today) -- WASHINGTON -- Another ileal bile acid transporter inhibitor has demonstrated in a phase III trial the ability to reduce pruritus and serum bile acids for kids with progressive familial intrahepatic cholestasis (PFIC). In children... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - November 9, 2022 Category: Dermatology Source Type: news

Odevixibat Scratches the Itch of Kids' Rare Liver Disease
(MedPage Today) -- Odevixibat (Bylvay) reduced intense itching and serum bile acids in children with progressive familial intrahepatic cholestasis (PFIC), as detailed in the publication of the PEDFIC 1 trial results that led to the drug's recent... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - July 8, 2022 Category: Dermatology Source Type: news

FDA OKs Odevixibat for Pruritus Associated With Rare Liver Disease FDA OKs Odevixibat for Pruritus Associated With Rare Liver Disease
Odevixibat (Bylvay) is the first drug approved for the treatment of severe itching in children as young as 3 months with progressive familial intrahepatic cholestasis.FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - July 21, 2021 Category: Drugs & Pharmacology Tags: Gastroenterology News Source Type: news

FDA Approves Bylvay (odevixibat) for the Treatment of Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)
BOSTON, July 20, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced U.S. Food& Drug Administration (FDA) approval of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 20, 2021 Category: Drugs & Pharmacology Source Type: news

Albireo gets FDA, European approval for pediatric liver disease drug
Albireo Pharma, a rare liver disease-focused biopharma spun out of AstraZeneca in 2008, has its first regulatory approval for a drug for a pediatric liver disease called progressive familial intrahepatic cholestasis (PFIC). (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 20, 2021 Category: Biotechnology Authors: Rowan Walrath Source Type: news

Albireo gets FDA, European approval for pediatric liver disease drug
Albireo Pharma, a rare liver disease-focused biopharma spun out of AstraZeneca in 2008, has its first regulatory approval for a drug for a pediatric liver disease called progressive familial intrahepatic cholestasis (PFIC). (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 20, 2021 Category: Pharmaceuticals Authors: Rowan Walrath Source Type: news

She was pregnant and terribly itchy. Something was going very wrong.
The ailment was intrahepatic cholestasis of pregnancy, which causes a toxic womb environment and can lead to stillbirths. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - December 8, 2019 Category: Consumer Health News Authors: Claire Marie Porter Source Type: news

Ursodeoxycholic Acid Ineffective for Liver Disorder of Pregnancy Ursodeoxycholic Acid Ineffective for Liver Disorder of Pregnancy
Ursodeoxycholic acid, the currently recommended treatment for intrahepatic cholestasis of pregnancy (ICP), does not reduce adverse perinatal outcomes and its routine use"should be reconsidered," conclude investigators in the PITCHES randomized controlled trial.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 10, 2019 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health News Source Type: news

Common Therapy for Obstetric Cholestasis Found Ineffective
WEDNESDAY, Aug. 7, 2019 -- For women with intrahepatic cholestasis of pregnancy, treatment with ursodeoxycholic acid does not reduce adverse perinatal outcomes, according to a study published online Aug. 1 in The Lancet. Lucy C. Chappell, Ph.D.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 7, 2019 Category: Pharmaceuticals Source Type: news

New connection found between NAFLD and rare pregnancy complication
(Digestive Disease Week) A new link has been found between a rare and serious condition that typically presents as itchy palms during pregnancy and the world's most common chronic liver disease, according to research presented at Digestive Disease Week ® (DDW) 2019. Researchers found that intrahepatic cholestasis of pregnancy (ICP), a bile acid disorder in adults that affects roughly one of every 300 pregnancies, may be associated with non-alcoholic fatty liver disease (NAFLD). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 9, 2019 Category: International Medicine & Public Health Source Type: news

What Does the Liver Do?
Discussion The liver is one of the largest organs in the body, weighing just over 3 pounds in an adult. It is found in the upper right abdomen, under the right dome of the diaphragm. Grossly, it has asymmetric lobes with the right being larger than the left. The lobes are separated by a fibrous connective tissue band that also anchors the liver in the abdominal cavity. The gallbladder is located on the inferior surface of the liver and stores bile, which is then released into the duodenum. Microscopically, the liver cells are arranged in lobules with canals carrying blood vessels and bile ducts. At any moment about 10-13% ...
Source: PediatricEducation.org - April 1, 2019 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Stillbirth Risk Up With High Serum Bile Acids in Pregnancy
TUESDAY, March 12, 2019 -- The risk of stillbirth is increased in women with intrahepatic cholestasis of pregnancy when serum bile acids concentrations are ≥100 µmol/L or more, according to a review published in the March 2 issue of The... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 12, 2019 Category: Pharmaceuticals Source Type: news

Albireo to initiate A4250 ’s Phase III clinical programme to treat PFIC
Albireo Pharma is planning to initiate a Phase III clinical programme of its product candidate A4250 in the second half of this year for the treatment of patients with progressive familial intrahepatic cholestasis (PFIC). (Source: Drug Development Technology)
Source: Drug Development Technology - May 21, 2017 Category: Pharmaceuticals Source Type: news

Discovery provides insight into life-threatening respiratory distress in newborns
St. Jude Children’s Research Hospital scientists advance understanding of intrahepatic cholestasis of pregnancy, a liver disorder that leaves infants born to affected mothers at risk for severe respiratory distress (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 29, 2015 Category: Science Source Type: news

Intrahepatic cholestasis of pregnancy linked with liver cancer
(University of Gothenburg) In a new study of more than 125,000 pregnant women in Sweden, researchers at the Sahlgrenska Academy found that the risk of hepatobiliary cancer and immune-mediated and cardiovascular diseases later in life is higher in women with intrahepatic cholestasis of pregnancy than in women without this condition. Their results are published in the Journal of Hepatology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 12, 2015 Category: Cancer & Oncology Source Type: news